NASDAQ · DRTS

Alpha Tau Medical Ltd. Ordinary Shares (DRTS)

$13.72+3.16%
Close Nov 6, 2026 · split-adjusted
Nov 6, 2026$13.72▲ 260.67% in range
Nov 6, 2025Low $3.47 · High $15.50Nov 6, 2026
What changed · written from our data
As of Nov 6, 2026

Alpha Tau Medical closed at $13.72 on Nov 6, up 3.16%, 11.5% below its 52-week closing high. Volume of 418.0K shares was 0.83× its 20-day average (close to normal).

Split-adjusted performance: -2.0% over one month, +61.2% over six months, +246.5% over one year.

Short interest was 3.4M shares at the Oct 15 settlement (5.4% of float, 8.2 days to cover).

Market cap$1.27B92.5M shares
Revenue · quarter——
Diluted EPS——
P/E · TTM—
Net margin—
Dividend yieldNone
52-week range3.47 – 15.50−11.5% from high
Volume418.0K0.83× 20-day avg
Volatility · 60d42.0%Annualised
Short % of float5.4%8.2 days to cover
Net cash$66.8MCash $73.1M
Next earnings—Not scheduled
Split-adjusted performance
1W +5.1%1M −2.0%3M +0.9%6M +61.2%YTD +177.2%1Y +246.5%3Y +301.2%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within industry

Not enough peers to rank

6-month momentum—
Revenue growth—
Net margin—
Value (low P/E)—
Size—

Short interest

Details →
Shares short3.4M−0.3% vs prior
Days to cover8.2Settled Oct 15
% of float5.4%
Short vol. 10d59.6%of daily volume

Quick answers

What does Alpha Tau Medical do?
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range.
What is DRTS's market cap?
$1.27B, based on the Nov 6 close of $13.72.
Does Alpha Tau Medical pay a dividend?
No regular cash dividend has been paid in the last year.
How much of DRTS is sold short?
3.4M shares, 5.4% of float, as of Oct 15, 2026.

About Alpha Tau Medical

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.

121 employeesListed Mar 8, 2022alphatau.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology